Roivant Sciences (ROIV) Net Equity Issued and Repurchased (2022 - 2023)
Roivant Sciences' (ROIV) quarterly Net Equity Issued and Repurchased came in at $199.8 million in Q4 2023, up 110.93% YoY from $94.7 million in Q4 2022, and up 110.93% on a QoQ basis from $94.7 million in Q4 2022.
Powered by 
Analysis
Roivant Sciences (ROIV) Net Equity Issued and Repurchased (2022 - 2023) Analysis & Trends
Roivant Sciences (ROIV) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $199.8 million in Q4 2023.
- Quarterly Net Equity Issued and Repurchased rose 110.93% year-over-year to $199.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $294.6 million (changed N/A YoY) and the FY2024 annual result came in at $199.8 million, down 35.95% from the prior year.
- Net Equity Issued and Repurchased advanced to $199.8 million in Q4 2023, from $94.7 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $199.8 million in Q4 2023 to a low of $94.7 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 25.18 Bn | 25.18 Bn | 1.16 Mn | - |